ReShape Lifesciences Inc. reported Impairment of long-lived assets for the third quarter ended September 30, 2023. For the quarter, the company reported Impairment of long-lived assets of $777,000 against $7,429,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1698 USD | -4.61% | +2.72% | -32.00% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.00% | 3.98M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023